Biofidelity Raises $23M in Series A+ Round
The UK-based cancer diagnostics company will use the funding to launch ASPYRE-Lung, its pyrophosphorolysis-based lung cancer mutation detection assay.
Stay updated with breaking news from Barnaby Balmforth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The UK-based cancer diagnostics company will use the funding to launch ASPYRE-Lung, its pyrophosphorolysis-based lung cancer mutation detection assay.
/PRNewswire/ -- Biofidelity, a pioneer in precision cancer diagnostics, has successfully completed a heavily oversubscribed $23 million Series A+ investment...
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
/PRNewswire/ -- Biofidelity, a pioneer in precision cancer diagnostics, has successfully completed a heavily oversubscribed $23 million Series A+ investment...
/PRNewswire/ -- Biofidelity, a pioneer in precision cancer diagnostics, has expanded its Scientific Advisory Board to include Lee N. Newcomer, MD, an...